November 14, 2025 a 11:43 am
WST: Fundamental Ratio Analysis - West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. is a prominent player in the medical supply industry, innovating containment and delivery systems for injectable drugs and healthcare products. With its dual-segment operation strategy, the company effectively targets both proprietary and contract-manufactured solutions. This comprehensive approach supports clients globally across the pharmaceutical and medical device sectors.
Fundamental Rating
West Pharmaceutical Services maintains a strong fundamental position with balanced performance across key metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
Consistency in historical performance indicates steady market presence.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-14 | 3 | 3 | 4 | 5 | 2 | 1 | 2 |
| 2025-11-13 | 3 | 3 | 4 | 5 | 2 | 1 | 2 |
Analysts' Price Targets
Analyst projections position WST for growth, reflecting strong market confidence with stable median price targets.
| High | Low | Median | Consensus |
|---|---|---|---|
| $390 | $311 | $345 | $345.2 |
Analysts' Sentiment
Current sentiment is leaning towards a buy recommendation, suggesting positive outlooks from analysts.
| Rating | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 10 | |
| Hold | 3 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
West Pharmaceutical Services, Inc. stands on solid fundamentals with a strong market presence, indicated by consistent performance scores and analyst confidence. The company continues to innovate in its sector, maintaining robust relationships with pharmaceutical and medical partners. However, the mixed ratings in financial metrics suggest areas for improvement to sustain investor confidence. Future growth depends on strategic expansions and continued financial health management. Overall, the stock is poised for steady growth with moderate investment risk.